Search research articles
Contact Us
Filters
Showing results (61-70 of 73) with videos related to
Page
of 8
Sort By:
American Journal of Physiology. Endocrinology and Metabolism
|
August 30, 2008
Pharmacological characterization of a small molecule inhibitor of c-Jun kinase
Helen Cho, Shawn C Black, David Looper, et al.
Biochemical and Biophysical Research Communications
|
March 10, 2010
In vitro and in vivo pharmacology of CP-945,598, a potent and selective cannabinoid CB(1) receptor antagonist for the management of obesity
John R Hadcock, David A Griffith, Phillip A Iredale, et al.
BMC Pharmacology
|
August 18, 2010
Quantitative in vitro and in vivo pharmacological profile of CE-178253, a potent and selective cannabinoid type 1 (CB1) receptor antagonist
John R Hadcock, Philip A Carpino, Philip A Iredale, et al.
Journal of Veterinary Internal Medicine
|
November 3, 2020
Ecological level analysis of primary lung tumors in dogs and cats and environmental radon activity
Brittany L Fowler, Chad M Johannes, Annette O'Connor, et al.
Epilepsy Currents
|
March 14, 2025
Teratogenesis, Perinatal, and Neurodevelopmental Outcomes After In Utero Exposure to Antiseizure Medication
, Alison M Pack, Maryam Oskoui, et al.
Neurology
|
May 15, 2024
Teratogenesis, Perinatal, and Neurodevelopmental Outcomes After In Utero Exposure to Antiseizure Medication: Practice Guideline From the AAN, AES, and SMFM
Alison M Pack, Maryam Oskoui, Shawniqua Williams Roberson, et al.
Bioorganic & Medicinal Chemistry Letters
|
November 3, 2005
New bicyclic cannabinoid receptor-1 (CB1-R) antagonists
Philip A Carpino, David A Griffith, Subas Sakya, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
January 10, 2008
Correlating efficacy in rodent cognition models with in vivo 5-hydroxytryptamine1a receptor occupancy by a novel antagonist, (R)-N-(2-methyl-(4-indolyl-1-piperazinyl)ethyl)-N-(2-pyridinyl)-cyclohexane carboxamide (WAY-101405)
Warren D Hirst, Terrance H Andree, Suzan Aschmies, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 2, 2009
Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia
David P Rotella, Geraldine R McFarlane, Alexander Greenfield, et al.
Neurology
|
November 16, 2021
Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee
Tamara Pringsheim, Gregory S Day, Don B Smith, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 73) with videos related to
Sort By:
Page
of 8
American Journal of Physiology. Endocrinology and Metabolism
|
August 30, 2008
Pharmacological characterization of a small molecule inhibitor of c-Jun kinase
Helen Cho, Shawn C Black, David Looper, et al.
Biochemical and Biophysical Research Communications
|
March 10, 2010
In vitro and in vivo pharmacology of CP-945,598, a potent and selective cannabinoid CB(1) receptor antagonist for the management of obesity
John R Hadcock, David A Griffith, Phillip A Iredale, et al.
BMC Pharmacology
|
August 18, 2010
Quantitative in vitro and in vivo pharmacological profile of CE-178253, a potent and selective cannabinoid type 1 (CB1) receptor antagonist
John R Hadcock, Philip A Carpino, Philip A Iredale, et al.
Journal of Veterinary Internal Medicine
|
November 3, 2020
Ecological level analysis of primary lung tumors in dogs and cats and environmental radon activity
Brittany L Fowler, Chad M Johannes, Annette O'Connor, et al.
Epilepsy Currents
|
March 14, 2025
Teratogenesis, Perinatal, and Neurodevelopmental Outcomes After In Utero Exposure to Antiseizure Medication
, Alison M Pack, Maryam Oskoui, et al.
Neurology
|
May 15, 2024
Teratogenesis, Perinatal, and Neurodevelopmental Outcomes After In Utero Exposure to Antiseizure Medication: Practice Guideline From the AAN, AES, and SMFM
Alison M Pack, Maryam Oskoui, Shawniqua Williams Roberson, et al.
Bioorganic & Medicinal Chemistry Letters
|
November 3, 2005
New bicyclic cannabinoid receptor-1 (CB1-R) antagonists
Philip A Carpino, David A Griffith, Subas Sakya, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
January 10, 2008
Correlating efficacy in rodent cognition models with in vivo 5-hydroxytryptamine1a receptor occupancy by a novel antagonist, (R)-N-(2-methyl-(4-indolyl-1-piperazinyl)ethyl)-N-(2-pyridinyl)-cyclohexane carboxamide (WAY-101405)
Warren D Hirst, Terrance H Andree, Suzan Aschmies, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 2, 2009
Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia
David P Rotella, Geraldine R McFarlane, Alexander Greenfield, et al.
Neurology
|
November 16, 2021
Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee
Tamara Pringsheim, Gregory S Day, Don B Smith, et al.
Page
of 8